Additionally, in a preclinical study, they demonstrated that anti-CD47 therapy enhanced the proinflammatory response of immune cells and then CD8+ T cell infiltration density increased in ESCC tissue in vivo (63), indicating that the CD47/SIRPα axis might serve as a novel immunotherapeutic target for patients with ESCC. The gene discussed is CD8A; the disease is esophageal squamous cell carcinoma.